XML 83 R71.htm IDEA: XBRL DOCUMENT v3.21.4
BUSINESS COMBINATIONS (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 02, 2021
USD ($)
shares
Jul. 09, 2021
USD ($)
May 03, 2021
USD ($)
shares
Apr. 30, 2021
USD ($)
Nov. 08, 2019
USD ($)
Apr. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
USD ($)
Dec. 01, 2019
USD ($)
Nov. 29, 2019
USD ($)
BUSINESS COMBINATIONS                      
Consideration in cash               $ 41,590,000 $ 3,931,000    
Income tax benefit               4,776,000 (147,000)    
Contingent consideration             $ 640,000 640,000      
Revenues               89,605,000 60,469,000    
Net loss               10,895,000 (4,685,000)    
Pre-Clinical Research Services, Inc.                      
BUSINESS COMBINATIONS                      
Contingent consideration         $ 5,857,000            
Transaction consideration in business acquisition         1,500,000            
Common shares value         240,000           $ 1,133,000
Payments for purchase of certain real property         2,500,000            
Intangible assets             2,081,000 2,081,000   $ 5,857,000  
Transaction costs               248,000      
Revenues               7,770,000 4,780,000    
Net loss               177,000 176,000    
Pre-Clinical Research Services, Inc. | Unsecured promissory note                      
BUSINESS COMBINATIONS                      
Principal amount         $ 800,000            
Annual interest rate         4.50%            
HistoTox Labs                      
BUSINESS COMBINATIONS                      
Consideration in cash       $ 22,389,000              
Adjustments for net working capital           $ 68,000          
Intangible assets             8,500,000 8,500,000      
Transaction costs               576,000      
Goodwill deductible for tax purposes             10,804,000 10,804,000      
Bolder BioPATH                      
BUSINESS COMBINATIONS                      
Adjustments for net working capital     $ 970,000                
Shares issued | shares     1,588,235                
Common shares value     $ 34,452,000                
Principal amount     $ 1,500,000                
Annual interest rate     4.50%                
Escrowed amount     $ 1,250,000                
Intangible assets             12,500,000 12,500,000      
Cash and equivalents assumed     $ 17,530,000                
Transaction costs               584,000      
Income tax benefit               4,867,000      
Decrease in goodwill             (970,000)        
Decrease in total consideration             970,000        
Goodwill deductible for tax purposes             0 $ 0      
Acquisition term               1 year      
Goodwill impairment losses               $ 0      
Gateway Pharmacology Laboratories LLC                      
BUSINESS COMBINATIONS                      
Shares issued | shares 45,323                    
Common shares value $ 1,182,000                    
Intangible assets             100,000 100,000      
Cash and equivalents assumed 1,671,000                    
Transaction costs               93,000      
Income tax benefit $ 118,000                    
Goodwill deductible for tax purposes             0 $ 0      
Acquisition term               1 year      
Goodwill impairment losses               $ 0      
HistoTox Labs and Bolder BioPATH combined                      
BUSINESS COMBINATIONS                      
Transaction costs                 $ 1,128,000    
Number of operating segments | segment               1      
Revenues               $ 11,343,000      
Net loss               $ 2,017,000      
HistoTox Labs and Bolder BioPATH combined | Minimum                      
BUSINESS COMBINATIONS                      
Weighted-average estimated useful life               6 years      
HistoTox Labs and Bolder BioPATH combined | Maximum                      
BUSINESS COMBINATIONS                      
Weighted-average estimated useful life               8 years      
Paycheck protection program loan | Unsecured promissory note                      
BUSINESS COMBINATIONS                      
Principal amount             800,000 $ 800,000      
BioReliance Corporation                      
BUSINESS COMBINATIONS                      
Intangible assets             640,000 $ 640,000      
Cash and equivalents assumed   $ 175,000                  
Percentage of net sales from services to existing customers   10.00%           10.00%      
Percentage of estimated fair value of net sales   10.00%                  
Contingent consideration   $ 640,000         $ 640,000 $ 640,000      
Acquisition term   1 year                  
Goodwill impairment losses   $ 0                  
BioReliance Corporation | Accrued Liabilities, Current                      
BUSINESS COMBINATIONS                      
Contingent consideration   $ 175,000                  
Customer Relationships | HistoTox Labs                      
BUSINESS COMBINATIONS                      
Weighted-average estimated useful life               8 years      
Customer Relationships | Bolder BioPATH                      
BUSINESS COMBINATIONS                      
Weighted-average estimated useful life               8 years      
Non-Compete Agreements | HistoTox Labs                      
BUSINESS COMBINATIONS                      
Weighted-average estimated useful life               5 years